Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.

Trial Details

NCT ID
NCT05761470
Phase
PHASE2
Sponsor
Ying Lin
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Camrelizumab
  • Fluzoparib
  • Nab-paclitaxel
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Histologically documented Her-2 negative
  • TNM stage: T1c, N1-N2;T2-4, N0-N2;any T, N3
  • No distant metastatic disease
  • Eastern Cooperative Oncology Group Performance Status: 0\~1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →